Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SMTI
stocks logo

SMTI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
27.78M
+5.59%
0.325
-280.56%
28.10M
+19.91%
0.260
-163.41%
29.55M
+14.4%
0.290
-226.09%
Estimates Revision
The market is revising Downward the revenue expectations for Sanara MedTech Inc. (SMTI) for FY2025, with the revenue forecasts being adjusted by -0.76% over the past three months. During the same period, the stock price has changed by -35.06%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.76%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-53.25%
In Past 3 Month
Stock Price
Go Down
down Image
-35.06%
In Past 3 Month
Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 21.800
sliders
Low
36.00
Averages
41.00
High
46.00
Current: 21.800
sliders
Low
36.00
Averages
41.00
High
46.00
H.C. Wainwright
Buy
downgrade
$54 -> $36
2025-11-14
Reason
H.C. Wainwright
Price Target
$54 -> $36
2025-11-14
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Sanara MedTech to $36 from $54 and keeps a Buy rating on the shares following the Q3 report. The company plans to execute its commercial plan and improve operational efficiency to support sustainable revenue growth and improved profitability going forward, the analyst tells investors in a research note.
H.C. Wainwright
Yi Chen
Buy
maintain
$53 -> $54
2025-08-18
Reason
H.C. Wainwright
Yi Chen
Price Target
$53 -> $54
2025-08-18
maintain
Buy
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $54 from $53 and keeps a Buy rating on the shares. The company reported a Q2 beat, the analyst tells investors in a research note.
H.C. Wainwright
Yi Chen
Buy
maintain
$51 -> $53
2025-05-15
Reason
H.C. Wainwright
Yi Chen
Price Target
$51 -> $53
2025-05-15
maintain
Buy
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on Sanara MedTech to $53 from $51 and keeps a Buy rating on the shares following the Q1 report. The firm believes Sanara Surgical segment could continue to drive sales growth as the company increases regional sales managers and territories and grows distribution partners.
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$46
2025-03-26
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$46
2025-03-26
Reiterates
Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$50 → $51
2025-03-26
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$50 → $51
2025-03-26
Maintains
Strong Buy
Reason
Cantor Fitzgerald
Ross Osborn
Buy
Reiterates
$44
2025-01-23
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$44
2025-01-23
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sanara Medtech Inc (SMTI.O) is 18.79, compared to its 5-year average forward P/E of -10.47. For a more detailed relative valuation and DCF analysis to assess Sanara Medtech Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.47
Current PE
18.79
Overvalued PE
64.76
Undervalued PE
-85.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
3.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.32
Undervalued EV/EBITDA
-10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.62
Current PS
0.00
Overvalued PS
7.11
Undervalued PS
2.14
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SMTI News & Events

Events Timeline

(ET)
2025-11-12
07:14:51
Sanara MedTech announces Q3 earnings per share of $3.40 compared to a loss of 34 cents last year.
select
2025-11-11 (ET)
2025-11-11
16:15:42
Sanara MedTech ceases operations of Tissue Health Plus division
select
2025-09-02 (ET)
2025-09-02
16:32:39
Sanara MedTech CEO Ron Nixon Steps Down, Seth Yon to Take Over
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-24Globenewswire
Investor Notice: Holzer & Holzer, LLC Launches Investigation into Sanara MedTech Inc. (SMTI)

  • Investigation Announcement: Holzer & Holzer, LLC is investigating Sanara MedTech Inc. for potential violations of federal securities laws following the company's announcement of a strategic realignment and discontinuation of its Tissue Health Plus operations, which led to a drop in stock price.

  • Investor Outreach: Investors who purchased Sanara stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance regarding their rights.

  • Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has successfully recovered significant amounts for shareholders affected by corporate misconduct since its establishment in 2000.

  • Contact Information: Interested parties can reach out to Corey Holzer or Joshua Karr via email or phone for more information about the investigation and potential legal actions.

[object Object]
Preview
1.0
11-19Newsfilter
Sanara MedTech to Attend the 37th Annual Healthcare Conference Hosted by Piper Sandler on December 3rd

  • Company Participation in Conference: Sanara MedTech Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025, with a scheduled presentation on December 3 at 9:30 a.m. ET.

  • Product Offerings: The company specializes in developing and marketing surgical products aimed at improving clinical outcomes and reducing healthcare costs, with a focus on the North American surgical tissue repair market.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's business strategy, product development, and potential risks associated with regulatory approvals and market acceptance.

  • Investor Relations: Additional information and presentation materials will be available on the company's investor relations website, along with a live audio webcast and an archive for later access.

[object Object]
Preview
4.5
11-16Yahoo Finance
Sanara MedTech (SMTI) Shifts Focus Following THP Division Closure and Quarterly Losses

  • Sanara MedTech's Business Realignment: The company has discontinued its Tissue Health Plus division to focus on its core surgical segment, reporting third-quarter earnings of $26.33 million in sales and a net loss of $30.41 million.

  • Future Growth Projections: Sanara anticipates $144.9 million in revenue and $1.9 million in earnings by 2028, based on a projected annual revenue growth rate of 14.2%, with a fair value estimate ranging from $18.41 to $41.00 per share.

  • Impact on Investment Outlook: Investors need to consider the potential of Sanara's surgical segment for future profitability, as the exit from THP addresses short-term risks but may affect resource allocation and operational priorities.

  • Market Sentiment and Analysis: The article emphasizes the importance of ongoing net losses and business realignment on future earnings, while also providing a comprehensive analysis of Sanara MedTech's financial health for potential investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sanara Medtech Inc (SMTI) stock price today?

The current price of SMTI is 21.8 USD — it has increased 3.46 % in the last trading day.

arrow icon

What is Sanara Medtech Inc (SMTI)'s business?

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.

arrow icon

What is the price predicton of SMTI Stock?

Wall Street analysts forecast SMTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SMTI is 41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sanara Medtech Inc (SMTI)'s revenue for the last quarter?

Sanara Medtech Inc revenue for the last quarter amounts to 26.33M USD, increased 21.51 % YoY.

arrow icon

What is Sanara Medtech Inc (SMTI)'s earnings per share (EPS) for the last quarter?

Sanara Medtech Inc. EPS for the last quarter amounts to -3.52 USD, increased 935.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sanara Medtech Inc (SMTI)'s fundamentals?

The market is revising Downward the revenue expectations for Sanara MedTech Inc. (SMTI) for FY2025, with the revenue forecasts being adjusted by -0.76% over the past three months. During the same period, the stock price has changed by -35.06%.
arrow icon

How many employees does Sanara Medtech Inc (SMTI). have?

Sanara Medtech Inc (SMTI) has 141 emplpoyees as of December 05 2025.

arrow icon

What is Sanara Medtech Inc (SMTI) market cap?

Today SMTI has the market capitalization of 195.87M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free